IN SB0066

Permits eligible individuals with terminal illnesses to access investigational drugs, biological products, or devices that have completed Phase I clinical trials and are under investigation by the FDA, but not yet approved for general use.

Defines "eligible individual" as a patient whose treating physician documents a terminal illness, confirms the patient has considered all FDA-approved treatment options, recommends investigational treatment, and obtains signed informed consent from the patient or their representative.

Requires informed consent documentation signed by the patient or representative, treating physician, and a witness that discloses potential outcomes including death, clarifies financial liability, and explains hospice care eligibility changes.

Manufacturers are not required to provide investigational treatments, and health plans and government agencies are not required to cover costs, with individuals bearing financial responsibility unless otherwise contractually agreed.

Prohibits the medical licensing board from disciplining treating physicians based solely on recommending investigational treatments to eligible patients, and makes it a Class B misdemeanor for state officials to prevent eligible individuals from receiving such treatment.